<DOC>
	<DOCNO>NCT02163122</DOCNO>
	<brief_summary>This pilot trial cat allergic participant , design compare allergic response participant specific allergen two method exposure . The method exposure use : environment exposure chamber ( EEC ) nasal allergen challenge ( NAC ) . Potential participant screen evidence cat allergy . Participants range allergic sensitivity cat allergen enrol . To help ensure breadth level allergic sensitivity among participant , individual high low exposure cat allergen daily life enrol .</brief_summary>
	<brief_title>Cat Pilot Study - Environmental Exposure Chamber ( EEC ) vs. Nasal Allergen Challenge ( NAC )</brief_title>
	<detailed_description />
	<mesh_term>Hypersensitivity</mesh_term>
	<mesh_term>Hypersensitivity , Immediate</mesh_term>
	<criteria>1 . History moderate severe allergic rhinitis ( AR ) cause cat exposure least 2 year . 2 . Skin prick test mean wheal diameter ≥ 5 mm large negative control standardize cat extract screening . 3 . Nonpregnant , nonlactating woman . For woman childbearing age , willingness use effective form contraception duration trial . 4 . In general good health base medical history physical exam . 5 . The ability give inform consent comply study procedure . 1 . A history anaphylaxis cat allergen . 2 . Prebronchodilator FEV1 le 80 % predict value screen visit . 3 . History moderate/severe ARIA ( Allergic Rhinitis Impact Asthma ) severity classification allergic rhinitis previous year absence cat exposure ( ARIA classification citation : Bousquet J , Khaltaev N , Cruz AA , et al . Allergy 2008 ; 63 Suppl 86:8160 . ) 4 . History asthma symptom exacerbation past 12 month require regular inhaled corticosteroid great 4 week per year , oral corticosteroid usage , emergency department visit asthma asthmarelated hospitalization . 5 . Participants , discretion investigator , suffer seasonal allergic rhinitis interfere allergen complete study outside local pollen season significant allergy perennial allergen avoid study . 6 . History serious chronic medical condition might interfere treatment assessment may pose additional risk participation study . 7 . History chronic obstructive pulmonary disease ( COPD ) . 8 . History significant recurrent acute sinusitis , define 2 episode per year last 2 year , require antibiotic treatment . 9 . History chronic sinusitis , define sinus symptom last great 12 week include 2 major factor 1 major factor 2 minor factor . Major factor define facial pain pressure , nasal obstruction blockage , nasal discharge purulence discolor postnasal discharge , purulence nasal cavity , impaired loss smell . Minor factor define headache , fever , halitosis , fatigue , dental pain , cough , ear pain , pressure , fullness . 10 . History systemic disease affect immune system autoimmune disease , immune complex disease , immunodeficiency , , opinion study physician , participation trial would pose risk significant effect immune system . 11 . Evidence active suspect bacterial , viral , fungal parasitic infection within 30 day prior allergen challenge . 12 . Exposure individual active tuberculosis within six month prior allergen challenge . 13 . At time allergen challenge , current symptom , treatment , upper respiratory tract infection , acute sinusitis , acute otitis medium , relevant infectious process ; serous otitis medium exclusion criterion . Participants may reevaluate eligibility symptom resolve . 14 . History cancer within last 5 year , except nonmelanoma skin cancer , stage 1 renal cell carcinoma , stage 1 prostate cancer cure local resection curatively treat carcinomas situ . 15 . Any tobacco smoking within last year history ≥10 pack year . 16 . Allergen immunotherapy treatment cat within previous 5 year . 17 . Any history grade 4 anaphylaxis due cause define CTCAE grade criterion . 18 . History bleed disorder , treatment anticoagulation antiplatelet therapy chronic treatment aspirin cardiovascular prophylaxis . 19 . Treatment omalizumab within 6 month prior NAC EEC procedure . 20 . Currently take follow medication : beta blocker ; tricyclic antidepressant ; monoamine oxidase inhibitor . 21 . Ongoing systemic immunosuppressive treatment . 22 . History intolerance rescue medication excipients . 23 . For woman childbearing age positive urine pregnancy test sensitivity le 50 mIU/mL . 24 . The use investigational drug within 30 day NAC EEC procedure . 25 . The presence medical condition investigator deem incompatible participation trial . 26 . Any clinically significant abnormal find physical examination , vital sign laboratory result screen deemed Investigator . 27 . Any clinically significant physical finding nasal anatomical deformity ( include presence nasal mucosal ulceration , nasal polyp , purulent secretion , septal perforation major abnormality nose ) , discretion Investigator , would interfere study procedure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Cat Allergy</keyword>
	<keyword>Feld1</keyword>
</DOC>